PRECLINICAL DEVELOPMENT OF THE PI3K ALPHA SELECTIVE AND PIK3CA MUTANT SELECTIVE INHIBITOR GDC-0077 AND PREDICTION OF ITS HUMAN PHARMACOKINETICS

被引：0

作者：

Pang, Jodie ^{[1
]}

Baumgardner, Matthew ^{[1
]}

Braun, Marie-Gabrielle ^{[1
]}

Cheong, Jonathan ^{[1
]}

Edgar, Kyle ^{[1
]}

Friedman, Lori ^{[1
]}

Hanan, Emily ^{[1
]}

Jaochico, Allan ^{[1
]}

Ma, Shuguang ^{[1
]}

Plise, Emile ^{[1
]}

Schmidt, Stephen ^{[1
]}

Liu, Ning ^{[1
]}

Song, Kyung ^{[1
]}

Staben, Steve ^{[1
]}

Salphati, Laurent ^{[1
]}

机构：

[1] Genentech Inc, San Francisco, CA USA

来源：

DRUG METABOLISM AND PHARMACOKINETICS | 2019年 / 34卷 / 01期

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

P56

引用

页码：S37 / S37

页数：1

共 50 条

[41] PIK3CA Mutations PREDICT RESPONSE TO PI3K/AKT/mTOR INHIBITORS
不详
CANCER DISCOVERY, 2012, 2 (03) : 205 - 205
[42] PI3K expression and PIK3CA mutations are related to colorectal cancer metastases
Zhu, Yu-Fen
Yu, Bao-Hua
Li, Da-Li
Ke, Hong-Lin
Guo, Xian-Zhi
Xiao, Xiu-Ying
WORLD JOURNAL OF GASTROENTEROLOGY, 2012, 18 (28) : 3745 - 3751
[43] PI3K expression and PIK3CA mutations are related to colorectal cancer metastases
Yu-Fen Zhu
World Journal of Gastroenterology, 2012, (28) : 3745 - 3751
[44] RETRACTED: Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216 (Retracted Article)
Walls, Marlena
Baxi, Sangita M.
Mehta, Pramod P.
Liu, Kevin K-C
Zhu, JinJiang
Estrella, Heather
Li, Chunze
Zientek, Michael
Zong, Qing
Smeal, Tod
Yin, Min-Jean
CLINICAL CANCER RESEARCH, 2014, 20 (03) : 631 - 643
[45] Process development of PI3K inhibitor GDC-0980
Humphries, Theresa
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248
[46] The PI3K inhibitor GDC-0032 enhances the efficacy of standard of care therapeutics in PI3K alpha mutant breast cancer models
Sampath, D.
Nannini, M. A.
Jane, G.
Hong, R.
Parsons, K. L.
Belvin, M.
Friedman, L. S.
Wallin, J. J.
CANCER RESEARCH, 2013, 73
[47] More antitumor efficacy of the PI3K inhibitor GDC-0941 in breast cancer with PIK3CA mutation or HER2 amplification status in vitro
Zheng, Jie
Wang, Huan
Yao, Jia
Zou, Xianjin
PHARMAZIE, 2014, 69 (01): : 38 - 42
[48] Preclinical characterization of the absorption and disposition of the brain penetrant PI3K/mTOR inhibitor paxalisib and prediction of its pharmacokinetics and efficacy in human
Salphati, Laurent
Pang, Jodie
Alicke, Bruno
Plise, Emile G.
Cheong, Jonathan
Jaochico, Allan
Olivero, Alan G.
Sampath, Deepak
Wong, Susan
Zhang, Xiaolin
XENOBIOTICA, 2024, 54 (02) : 64 - 74
[49] Comparative molecular dynamics analyses on PIK3CA hotspot mutations with PI3K alpha specific inhibitors and ATP
Mentes, Muratcan
Karakuzulu, Basak Buse
Ucar, Gonlum Bahar
Yandim, Cihangir
COMPUTATIONAL BIOLOGY AND CHEMISTRY, 2022, 99
[50] Double PIK3CA mutations in cis enhance PI3Kα oncogene activation and sensitivity to PI3Kα inhibitors in breast cancer
Vasan, N.
Razavi, P.
Johnson, J. L.
Shao, H.
Reznik, E.
Smith, M. L.
Sebra, R.
Cantley, L. C.
Scaltriti, M.
Baselga, J.
ANNALS OF ONCOLOGY, 2019, 30 : 1 - 1

← 1 2 3 4 5 →